Rotigotine
From Wikipedia, the free encyclopedia
 |
|
|
Rotigotine
|
|
| Systematic (IUPAC) name | |
| 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol | |
| Identifiers | |
| CAS number | |
| ATC code | N04 |
| PubChem | |
| Chemical data | |
| Formula | C19H25NOS |
| Mol. mass | 315.474 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 37% (transdermal) |
| Protein binding | 92% |
| Metabolism | Hepatic (CYP-mediated) |
| Half life | 5 to 7 hours |
| Excretion | Renal (71%) and fecal (23%) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Transdermal patch |
Rotigotine is a non-ergoline dopamine agonist drug developed by Schwarz Pharma AG for the treatment of Parkinson's disease. Rotigotine is intended to be delivered through transdermal patches, so as to ensure a slow and constant dosage in a 24 hour period. The transdermal patch form of the drug has been given the trade name Neupro.
The drug has been approved by the EMEA for use in all countries Of the EU, and is today being sold in several European countries under the German owned brand of Schwarz Pharma AG; the legal owner of the patch since 2005. As of 2006, the phase III clinical trial results showed that the drug was able to significantly reduce off time and increase on time without troublesome dyskinesia. The patch is under evaluation by the Food and Drug Administration (FDA) and awaiting approval in the United States.
[edit] See also
[edit] External links
- Manufacturer's webpage
- Website [1] for Neupro
- BBC News article: Skin patch hope for Parkinson's
- Medscape article: Transdermal Rotigotine Patch Safe, Effective in Early Idiopathic Parkinson's Disease
- Bandolier article: Rotigotine for restless legs syndrome - concludes that there is insufficient evidence for the use of rotigotine for treating RLS
- Owner's webpage for Neupro
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
